Soligenix, Inc. will present preclinical efficacy findings from its RiVax™ ricin toxin vaccine program at the National Organization for Rare Disorders’ (NORD’s) Rare Diseases and Orphan Products Breakthrough Summit on October 17-18, 2016 in Arlington, VA.
RiVax is the company’s proprietary vaccine candidate for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix’s proprietary heat-stabilization ThermoVax® technology, RiVax™ has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models.
The presented results, titled “Orphan Disease, Biodefense and the Animal Rule: A Thermostabilized Ricin Toxin Vaccine,” will be available for viewing throughout the conference and will address preclinical efficacy findings.
More details about the conference can be found at http://rarediseases.org/summit-overview/.
